Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/42—One nitrogen atom

Definitions

• Estrogen receptor (ER) and overexpressed Her2 are two major oncogenic proteins in hormone positive breast cancers. Current treatments to block ER or Her2 have been shown to effectively slow tumor growth. However, the need to overcome arising drug resistance has led to the development of combination and adjuvant drugs as new therapeutic approaches.
• Phosphatidylinositide 3-kinases PI 3-kinases, PI3Ks, PI(3)Ks, PI-3Ks,
• phosphatidylinositol-3 -kinases are a family of enzymes involved in cellular functions, such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.
• PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol.
• Histone deacetylase (HDAC) inhibition can cause breast cancer cell growth arrest, and has been reported to repress both ER and Her2 transcription.
• Class I HDAC inhibition leads to significant adverse effects and an alternative HDAC inhibition profile is desirable, particularly in combination with other therapeutic agents.
• HDAC6 is a Class lib HDAC and is known to remove acetyl groups from many cellular proteins, including a-tubulin and HSP90. It has been reported that HSP90 hyperacetylation destabilizes its target proteins, including ER and EGFR. Inhibitors of HDAC6 have demonstrated anti-cancer proliferative activity in various cancer types, including Her2 + breast cancer. Blocking HDAC6 activity has been shown to cause Her2 + breast cancer cell growth inhibition through various mechanisms, including destabilization of Her2 mRNA and protein.
• HDAC inhibitors Due to the dose-limiting toxicities of the non-selective HDAC inhibitors, there is an ongoing need in the art for more efficacious and less toxic compositions and methods for the treatment of breast cancer.
• pharmaceutical combinations comprising an HDAC inhibitor and either a Her2 inhibitor or a PI3K inhibitor, and methods for the treatment of breast cancer.
• the combinations and methods of the invention are well tolerated and do not exhibit the dose-limiting toxicities of prior therapies.
• compositions for the treatment of breast cancer in a subject in need thereof are provided herein. Also provided herein are methods for treating breast cancer in a subject in need thereof.
• HDAC histone deacetylase
• Her2 inhibitor for the treatment of breast cancer in a subject in need thereof.
• combinations comprising a histone deacetylase (HDAC) inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof.
• combinations comprising a histone deacetylase (HDAC) inhibitor and doxorubicin for the treatment of breast cancer in a subject in need thereof.
• kits for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of a combination comprising a histone deacetylase (HDAC) inhibitor and a Her2 inhibitor.
• methods for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of a combination comprising a histone deacetylase (HDAC) inhibitor and a PI3K inhibitor.
• the HDAC inhibitor is an HDAC6 specific inhibitor.
• the HDAC6 specific inhibitor is a compound of Formula I:
• ring B is aryl or heteroaryl
• P i is an aryl or heteroaryl, each of which may be optionally substituted by OH, halo, or Ci_ 6 -alkyl;
• R is H or Ci_6-alkyl.
• the HDAC6 specific inhibitor is a compound of Formula II:
• R X and R Y together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; each RA is independently Ci_ 6 -alkyl, Ci_ 6 -alkoxy, halo, OH, -N0 2 , -CN, or - NH 2 ; and
• n 0, 1, or 2.
• the compound of Formula II is:
• the compound of Formula II is:
• the Her2 inhibitor is lapatinib or pharmaceutically acceptable salts thereof.
• the PI3K inhibitor is IPI- 145 , GDC-0941 , or C AL- 101 , or pharmaceutically acceptable salts thereof.
• the HDAC inhibitor and the Her2 inhibitor are administered with a pharmaceutically acceptable carrier. In other embodiments, the HDAC inhibitor and the PI3 inhibitor are administered with a pharmaceutically acceptable carrier.
• the HDAC inhibitor and the Her2 inhibitor are administered in separate dosage forms. In other embodiments, the HDAC inhibitor and the Her2 inhibitor are administered in a single dosage form.
• the HDAC inhibitor and the PI3K inhibitor are administered in separate dosage forms. In other embodiments, the HDAC inhibitor and the PI3K inhibitor are administered in a single dosage form.
• the HDAC inhibitor and the Her2 inhibitor are administered at different times. In other embodiments, the HDAC inhibitor and the Her2 inhibitor are administered at substantially the same time.
• the HDAC inhibitor and the PI3K inhibitor are administered at different times. In other embodiments, the HDAC inhibitor and the PI3K inhibitor are administered at substantially the same time.
• the combination of the HDAC inhibitor and the Her2 inhibitor achieves a synergistic effect in the treatment of the subject in need thereof. In other embodiments, the combination of the HDAC inhibitor and the PI3K inhibitor achieves a synergistic effect in the treatment of the subject in need thereof.
• the HDAC6 specific inhibitor is a compound of Formula I:
• ring B is aryl or heteroaryl
• Ri is an aryl or heteroaryl, each of which may be optionally substituted by
• R is H or Ci_6-alkyl
• the Her2 inhibitor is any Her2 inhibitor.
• the HDAC6 specific inhibitor is:
• the Her2 inhibitor is lapatinib or a pharmaceutically acceptable salt thereof.
• the HDAC6 specific inhibitor is:
• the Her2 inhibitor is lapatinib or a pharmaceutically acceptable salt thereof.
• the HDAC6 specific inhibitor is a compound of Formula II:
• n 0, 1, or 2;
• the Her2 inhibitor is any Her2 inhibitor.
• the HDAC6 specific inhibitor is:
• the Her2 inhibitor is lapatinib or a pharmaceutically acceptable salt thereof.
• the HDAC6 specific inhibitor is:
• the Her2 inhibitor is lapatinib or a pharmaceutically acceptable salt thereof.
• the HDAC6 specific inhibitor is a compound of Formula I:
• ring B is aryl or heteroaryl
• Ri is an aryl or heteroaryl, each of which may be optionally substituted by OH, halo, or Ci_ 6 -alkyl;
• R is H or Ci_6-alkyl
• the PI3K inhibitor is any PI3K inhibitor.
• the HDAC6 specific inhibitor is:
• the PI3K inhibitor is selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or a pharmaceutically acceptable salt thereof.
• the HDAC6 specific inhibitor is:
• the PI3K inhibitor is selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or a pharmaceutically acceptable salt thereof.
• the HDAC6 specific inhibitor is a compound of Formula II:
• each R A is independently Ci_ 6 -alkyl, Ci_ 6 -alkoxy, halo, OH, -N0 2 , -CN, or - m is 0, 1, or 2;
• the PI3K inhibitor is any PI3K inhibitor.
• the HDAC6 specific inhibitor is:
• the PI3K inhibitor is selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or a pharmaceutically acceptable salt thereof.
• the HDAC6 specific inhibitor is:
• the PI3K inhibitor is selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or a pharmaceutically acceptable salt thereof.
• HDAC6 specific inhibitor may be any compound selected from the group consisting of Compound A, Compound B, Compound C, and Compound D.
• Figure 1 is a set of four graphs that show that the PI3K inhibitor GDC-0941 is potentiated by HDAC6 specific (selective) inhibitors.
• Figure 1 A shows the IC 5 o values for GDC-0941 at 0.05, 0.16, 0.5, 1.6, 5, and 16 ⁇ of Compound A.
• Figure IB shows the IC 50 values for GDC-0941 at 1.3, 4, and 12 ⁇ of Compound A.
• Figure 1C shows the IC 50 values for GDC-0941 at 1.3, 4, and 12 ⁇ of Compound C.
• Figure ID shows the IC 50 values for GDC-0941 at 0.5, 1.6, and 5 ⁇ of Compound C.
• Figure 2 is a pair of graphs that show the results of migration assays in A549 cells (lung cancer cells) ( Figure 2A) and MDA-MB-231 cells (breast cancer cells) ( Figure 2B) in which no EGF was used to stimulate cancer cell migration. In both assays, there was no pre- treatment with HDAC6 inhibitor. In both assays, Tubastatin A, Compound C, and
• Compound A were given in concentrations in which the drugs are HDAC6 selective inhibitors.
• Gefitinib is an EGFR inhibitor. ** means P ⁇ 0.01.
• Figure 3 is a pair of graphs that show the results of migration assays in A549 cells (lung cancer cells) ( Figure 3 A) and MDA-MB-231 cells (breast cancer cells) ( Figure 3B) in which EGF was used to stimulate cancer cell migration.
• Figure 3 A there was no pre- treatment with HDAC 6 inhibitor.
• Figure 3B there was pre-treatment with HDAC inhibitor, as HDAC6 inhibitors take time to act.
• Tubastatin A, Compound C, and Compound A were given in concentrations in which the drugs are HDAC6 selective inhibitors.
• Gefitinib is an EGFR inhibitor. Equal variance two-sample two-tailed t-test, normalized against DMSO + EGF group. ** means P ⁇ 0.01, * means P ⁇ 0.05.
• Figure 4 is a set of photographs that show MDA-MB-231 migration in DMSO (Figure 4A), 1 ⁇ Gefitinib (Figure 4B), 5 ⁇ Compound C (Figure 4C), 5 ⁇ Tubastatin A ( Figure 4D), and 0.5 ⁇ Compound A ( Figure 4E).
• Gefitinib is an EGFR inhibitor.
• Figure 5 is a pair of graphs that show the results of invasion assays in A549 cells (lung cancer cells) ( Figure 5 A) and MDA-MB-231 cells (breast cancer cells) ( Figure 5B) in which EGF was used to stimulate cancer cell migration. In both assays, Tubastatin A,
• the instant application is directed, generally, to combinations comprising a histone deacetylase (HDAC) inhibitor and a Her2 inhibitor, and methods for the treatment of breast cancer.
• the instant application is also directed, generally, to combinations comprising a histone deacetylase (HDAC) inhibitor and a PI3K inhibitor, and methods for the treatment of breast cancer.
• alkyl refers to saturated, straight- or branched-chain hydrocarbon moieties containing, in certain embodiments, between one and six, or one and eight carbon atoms, respectively.
• Examples of Ci- 6 -alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl moieties; and examples of Ci-g-alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl, heptyl, and octyl moieties.
• C x - y The number of carbon atoms in an alkyl substituent can be indicated by the prefix "C x - y ,” where x is the minimum and y is the maximum number of carbon atoms in the substituent.
• a C x chain means an alkyl chain containing x carbon atoms.
• alkoxy refers to an -O-alkyl moiety.
• cycloalkyl or "cycloalkylene” denote a monovalent group derived from a monocyclic or polycyclic saturated or partially unsaturated carbocyclic ring compound.
• C 3 -g-cycloalkyl examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl and cyclooctyl; and examples of C 3 -i 2 -cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl. Also contemplated are monovalent groups derived from a monocyclic or polycyclic carbocyclic ring compound having at least one carbon-carbon double bond by the removal of a single hydrogen atom.
• aryl refers to a mono- or poly-cyclic carbocyclic ring system having one or more aromatic rings, fused or non-fused, including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like.
• combination refers to two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such combination of therapeutic agents may be in the form of a single pill, capsule, or intravenous solution. However, the term “combination” also encompasses the situation when the two or more therapeutic agents are in separate pills, capsules, or intravenous solutions.
• combination therapy refers to the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, or in separate containers (e.g., capsules) for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
• heteroaryl refers to a mono- or poly-cyclic (e.g., bi-, or tri-cyclic or more) fused or non- fused, moieties or ring system having at least one aromatic ring, having from five to ten ring atoms of which one ring atom is selected from S, O, and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O, and N; and the remaining ring atoms are carbon.
• Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl, and the like.
• halo refers to a halogen, such as fluorine, chlorine, bromine, and iodine.
• HDAC histone deacetylases, which are enzymes that remove the acetyl groups from the lysine residues in core histones, thus leading to the formation of a condensed and transcriptionally silenced chromatin.
• Histone deacetylases There are currently 18 known histone deacetylases, which are classified into four groups.
• Class I HDACs which include HDACl , HDAC2, HDAC 3, and HDAC 8 are related to the yeast RPD3 gene.
• Class II HDACs which include HDAC4, HDAC 5, HDAC6, HDAC 7, HDAC 9, and HDAC IO, are related to the yeast Hdal gene.
• Class III HDACs which are also known as the sirtuins are related to the Sir2 gene and include SIRTl-7.
• Class IV HDACs which contains only HDACl 1, has features of both Class I and II HDACs.
• the term "HDAC” refers to any one or more of the 18 known histone deacetylases, unless otherwise specified.
• HDAC6 specific means that the compound binds to HDAC6 to a substantially greater extent, such as 5X, 10X, 15X, 20X greater or more, than to any other type of HDAC enzyme, such as HDACl or HDAC2. That is, the compound is selective for HDAC6 over any other type of HDAC enzyme.
• a compound that binds to HDAC6 with an IC 50 of 10 nM and to HDACl with an IC 50 of 50 nM is HDAC6 specific.
• a compound that binds to HDAC6 with an IC 50 of 50 nM and to HDACl with an IC 50 of 60 nM is not HDAC6 specific
• inhibitor is synonymous with the term antagonist.
• compositions for the treatment of breast cancer in a subject in need thereof are provided herein. Also provided herein are methods for treating breast cancer in a subject in need thereof.
• the combinations and methods of the invention comprise a histone deacetylase (HDAC) inhibitor.
• the HDAC inhibitor may be any HDAC inhibitor.
• the HDAC inhibitor may be selective or non-selective to a particular type of histone deacetylase enzyme.
• the HDAC inhibitor is a selective HDAC inhibitor. More preferably, the HDAC inhibitor is an HDAC6 specific inhibitor.
• the HDAC6 specific inhibitor is a compound of Formula I:
• ring B is aryl or heteroaryl
• P i is an aryl or heteroaryl, each of which may be optionally substituted by , halo, or Ci_ 6 -alkyl;
• R is H or Ci_6-alkyl.
• Representative compounds of Formula I include, but are not limited to:
• the HDAC6 specific inhibitor is a compound of Formula II:
• R x and R y together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; each R A is independently Ci_ 6 -alkyl, Ci_ 6 -alkoxy, halo, OH, -N0 2 , -CN, or - NH 2 ; and
• n 0, 1, or 2.
• Representative compounds of Formula II include, but are not limited to:
• the compounds described herein are unsolvated. In other embodiments, one or more of the compounds are in solvated form.
• the solvate can be any of pharmaceutically acceptable solvent, such as water, ethanol, and the like.
• Her2 inhibitor may be any Her2 inhibitor.
• Her2 inhibitors include, but are not limited to, lapatinib, trastuzumab, pertuzumab, NeuVax, cetuximab, and tyrosine kinase inhibitors.
• the Her2 inhibitor is lapatinib or a pharmaceutically acceptable salt thereof.
• the compounds described herein are unsolvated. In other embodiments, one or more of the compounds are in solvated form.
• the solvate can be any of pharmaceutically acceptable solvent, such as water, ethanol, and the like.
• PI3K inhibitor may be any PI3K inhibitor.
• PI3K inhibitors include, but are not limited to, Wortmannin, demethoxyviridin, LY294002, perifosine, CAL- 101, PX-866, IPI-145, BAY 80-6946, BEZ-235, RP-6503, TGR 1202, SF-1126, INK-1117, GDC-0941, BKM-120, XL-147, XL-765, Palomid 529, GSK-1059615, ZSTK-474, PWT- 33597, IC-87114, TG100-115, CAL-263, RP-6530, PI-103, GNE-477, CUDC-907, and AEZS-136.
• the PI3K inhibitor is selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or a pharmaceutical
• the compounds described herein are unsolvated. In other embodiments, one or more of the compounds are in solvated form.
• the solvate can be any of pharmaceutically acceptable solvent, such as water, ethanol, and the like.
• HDAC histone deacetylase
• Her2 inhibitor for the treatment of breast cancer in a subject in need thereof.
• combinations comprising a histone deacetylase (HDAC) inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof.
• the HDAC inhibitor is an HDAC6 specific inhibitor.
• the HDAC6 specific inhibitor is a compound of Formula I:
• the compound of Formula I is:
• the HDAC6 specific inhibitor is a compound of
• the compound of Formula II is:
• the compound of Formula II is:
• the Her2 inhibitor is any Her2 inhibitor or a pharmaceutically acceptable salt thereof.
• the Her2 inhibitor is lapatinib or a pharmaceutically acceptable salt thereof.
• the PI3K inhibitor is any PI3K inhibitor or a pharmaceutically acceptable salt thereof.
• the PI3K inhibitor is selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or a
• a combination therapy comprising an HDAC6 specific inhibitor and a Her2 inhibitor, wherein the HDAC6 specific inhibitor is a compound of Formula I:
• ring B is aryl or heteroaryl
• Ri is an aryl or heteroaryl, each of which may be optionally substituted by
• R is H or Ci_6-alkyl
• the Her2 inhibitor is any Her2 inhibitor.
• the HDAC6 specific inhibitor is:
• the Her2 inhibitor is lapatinib or a pharmaceutically acceptable salt thereof.
• a combination therapy comprising an
• HDAC6 specific inhibitor and a Her2 inhibitor, wherein the HDAC6 specific inhibitor is compound of Formula II:
• R x and R y together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; each R A is independently Ci_ 6 -alkyl, Ci_ 6 -alkoxy, halo, OH, -N0 2 , -CN, or - NH 2 ; and
• n 0, 1, or 2;
• the Her2 inhibitor is any Her2 inhibitor.
• the HDAC6 specific inhibitor is:
• the Her2 inhibitor is lapatinib or a pharmaceutically acceptable salt thereof.
• a combination therapy comprising an HDAC6 specific inhibitor and a PI3K inhibitor, wherein the HDAC6 specific inhibitor is a compound of Formula I:
• ring B is aryl or heteroaryl
• Ri is an aryl or heteroaryl, each of which may be optionally substituted by
• R is H or Ci_6-alkyl
• the PI3K inhibitor is any PI3K inhibitor.
• the HDAC6 specific inhibitor is:
• the PI3K inhibitor is selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or a pharmaceutically acceptable salt thereof.
• a combination therapy comprising an HDAC6 specific inhibitor and a PI3K inhibitor, wherein the HDAC6 specific inhibitor is a compound of Formula II: or a pharmaceutically acceptable salt thereof,
• R x and R y together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; each R A is independently Ci_ 6 -alkyl, Ci_ 6 -alkoxy, halo, OH, -N0 2 , -CN, or - NH 2 ; and
• n 0, 1, or 2;
• the PI3K inhibitor is any PI3K inhibitor.
• the HDAC6 specific inhibitor is:
• the PI3K inhibitor is selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or a pharmaceutically acceptable salt thereof.
• pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
• pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• the pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
• pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical
• such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
• the HDAC inhibitor (a compound of Formula I or II) is administered simultaneously with either the Her2 inhibitor or PI3K inhibitor.
• Simultaneous administration typically means that both compounds enter the patient at precisely the same time.
• simultaneous administration also includes the possibility that the HDAC inhibitor and either the Her2 inhibitor or PI3K inhibitor enter the patient at different times, but the difference in time is sufficiently miniscule that the first administered compound is not provided the time to take effect on the patient before entry of the second administered compound.
• Such delayed times typically correspond to less than 1 minute, and more typically, less than 30 seconds.
• simultaneous administration can be achieved by administering a solution containing the combination of compounds.
• simultaneous administration of separate solutions one of which contains the HDAC inhibitor and the other of which contains either the Her2 inhibitor or PI3K inhibitor
• simultaneous administration can be achieved by administering a composition containing the combination of compounds.
• simultaneous administration can be achieved by administering two separate compositions, one comprising the HDAC inhibitor and the other comprising either the Her2 inhibitor or PI3K inhibitor.
• the HDAC inhibitor and either the Her2 inhibitor or PI3K inhibitor are not administered simultaneously.
• the HDAC inhibitor is administered before either the Her2 inhibitor or PI3K inhibitor.
• either the Her2 inhibitor or PI3K inhibitor is administered before the HDAC inhibitor.
• the time difference in non-simultaneous administrations can be greater than 1 minute, five minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, two hours, three hours, six hours, nine hours, 12 hours, 24 hours, 36 hours, or 48 hours.
• the first administered compound is provided time to take effect on the patient before the second administered compound is administered. Generally, the difference in time does not extend beyond the time for the first administered compound to complete its effect in the patient, or beyond the time the first administered compound is completely or substantially eliminated or deactivated in the patient.
• one or both of the HDAC inhibitor and either the Her2 inhibitor or PI3K inhibitor are administered in a therapeutically effective amount or dosage.
• a “therapeutically effective amount” is an amount of HDAC6 inhibitor (a compound of Formula I or II) or either a Her2 inhibitor or PI3K inhibitor that, when administered to a patient by itself, effectively treats the breast cancer. An amount that proves to be a
• terapéuticaally effective amount in a given instance, for a particular subject, may not be effective for 100% of subjects similarly treated for the disease or condition under
• therapeutically effective amount is strongly dependent on the type of cancer, stage of the cancer, the age of the patient being treated, and other facts. In general, therapeutically effective amounts of these compounds are well-known in the art, such as provided in the supporting references cited above.
• one or both of the HDAC inhibitor and either the Her2 inhibitor or PI3K inhibitor are administered in a sub-therapeutically effective amount or dosage.
• a sub-therapeutically effective amount is an amount of HDAC inhibitor (a compound of Formula I or II) or either a Her2 inhibitor or PI3K inhibitor that, when administered to a patient by itself, does not completely inhibit over time the biological activity of the intended target.
• a sub-therapeutic amount of a compound of Her2 inhibitor or PI3K inhibitor can be an effective amount if, when combined with a compound of Formula I or II (HDAC inhibitor), the combination is effective in the treatment of breast cancer.
• the combination of compounds exhibits a synergistic effect
• synergistic effect refers to the action of two agents, such as, for example, a HDAC inhibitor and either a Her2 inhibitor or PI3K inhibitor, producing an effect, for example, slowing the symptomatic progression of cancer or symptoms thereof, which is greater than the simple addition of the effects of each drug administered by themselves.
• a synergistic effect can be calculated, for example, using suitable methods such as the Sigmoid-Emax equation (Holford, N. H. G. and Scheiner, L. B., Clin. Pharmacokinet. 6: 429-453 (1981)), the equation of Loewe additivity (Loewe, S.
• the combinations and methods include an HDAC inhibitor of Formula II and either a Her2 inhibitor or a PI3K inhibitor.
• the combinations and methods include Compound C and a Her2 inhibitor.
• the combinations and methods include Compound C and a PI3K inhibitor.
• the combinations and methods include Compound D and a Her2 inhibitor.
• the combinations and methods include Compound D and a PI3K inhibitor.
• the combination of compounds can inhibit breast cancer growth, achieve breast cancer stasis, or even achieve substantial or complete breast cancer regression.
• the amounts of a HDAC inhibitor and either a Her2 inhibitor or PI3K inhibitor should result in the effective treatment of breast cancer
• the amounts, when combined, are preferably not excessively toxic to the patient (i.e. , the amounts are preferably within toxicity limits as established by medical guidelines).
• a limitation on the total administered dosage is provided.
• the amounts considered herein are per day; however, half-day and two-day or three-day cycles also are considered herein.
• a daily dosage such as any of the exemplary dosages described above, is administered once, twice, three times, or four times a day for three, four, five, six, seven, eight, nine, or ten days.
• a shorter treatment time e.g. , up to five days
• a longer treatment time e.g., ten or more days, or weeks, or a month, or longer
• a once- or twice-daily dosage is administered every other day.
• each dosage contains both an HDAC inhibitor and either a Her2 inhibitor or PI3K inhibitor to be delivered as a single dosage, while in other embodiments, each dosage contains either a HDAC inhibitor and either a Her2 inhibitor or PI3K inhibitor to be delivered as separate dosages.
• Compounds of Formula I and II, or their pharmaceutically acceptable salts or solvate forms, in pure form or in an appropriate pharmaceutical composition, can be administered via any of the accepted modes of administration or agents known in the art.
• the compounds can be administered, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally.
• the dosage form can be, for example, a solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, pills, soft elastic or hard gelatin capsules, powders, solutions, suspensions, suppositories, aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
• a solid, semi-solid, lyophilized powder, or liquid dosage forms such as for example, tablets, pills, soft elastic or hard gelatin capsules, powders, solutions, suspensions, suppositories, aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
• administration is oral, particularly one in which a convenient daily dosage regimen can be adjusted according to the degree of severity of the disease to be treated.
• the HDAC inhibitor and either the Her2 inhibitor or PI3K inhibitor of the pharmaceutical combination can be administered in a single unit dose or separate dosage forms.
• pharmaceutical combination includes a combination of two drugs in either a single dosage form or separate dosage forms, i.e., the pharmaceutically acceptable carriers and excipients described throughout the application can be combined with an HDAC inhibitor and either a Her2 inhibitor or PI3K inhibitor in a single unit dose, as well as individually combined with a HDAC inhibitor and either a Her2 inhibitor or PI3K inhibitor when these compounds are administered separately.
• Auxiliary and adjuvant agents may include, for example, preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents.
• antibacterial and antifungal agents such as, parabens, chlorobutanol, phenol, sorbic acid, and the like.
• Isotonic agents such as sugars, sodium chloride, and the like, may also be included.
• Prolonged absorption of an injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
• the auxiliary agents also can include wetting agents, emulsifying agents, pH buffering agents, and antioxidants, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, and the like.
• Solid dosage forms can be prepared with coatings and shells, such as enteric coatings and others well-known in the art. They can contain pacifying agents and can be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds also can be in
• microencapsulated form if appropriate, with one or more of the above-mentioned excipients.
• Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., the HDAC inhibitors or Her2 inhibitors or PI3K inhibitors described herein, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1 ,3- butyl eneglycol, dimethyl formamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glyce
• the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of the compounds described herein, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a pharmaceutically acceptable excipient.
• the composition will be between about 5% and about 75% by weight of a compound described herein, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.
• the invention relates to methods for treating breast cancer in a subject in need thereof comprising administering to the subject a pharmaceutical combination of the invention.
• methods for treating breast cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a combination comprising an HDAC inhibitor and a Her2 inhibitor.
• methods for treating breast cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a combination comprising an HDAC inhibitor and a PI3 inhibitor.
• methods for treating breast cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a combination comprising a histone deacetylase (HDAC) inhibitor and doxorubicin.
• HDAC histone deacetylase
• the subject considered herein is typically a human. However, the subject can be any mammal for which treatment is desired. Thus, the methods described herein can be applied to both human and veterinary applications.
• treating indicates that the method has, at the least, mitigated abnormal cellular proliferation.
• the method can reduce the rate of breast cancer growth in a patient, or prevent the continued growth or spread of the breast cancer, or even reduce the overall reach of the breast cancer.
• provided herein is a method for treating breast cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound A and lapatinib, or pharmaceutically acceptable salts thereof.
• in another embodiment is a method for treating breast cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound B and lapatinib, or pharmaceutically acceptable salts thereof.
• in another embodiment is a method for treating breast cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound C and lapatinib, or pharmaceutically acceptable salts thereof.
• This embodiment exhibits synergy (also called potentiation in the Examples) such that sub-therapeutic amounts of Compound C may be used in the method.
• in another embodiment is a method for treating breast cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound D and lapatinib, or pharmaceutically acceptable salts thereof.
• This embodiment exhibits synergy (also called potentiation in the Examples) such that sub-therapeutic amounts of Compound D may be used in the method.
• in another embodiment is a method for treating breast cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound A and a PI3K inhibitor selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or pharmaceutically acceptable salts thereof.
• a PI3K inhibitor selected from the group consisting of IPI-145, GDC-0941, and CAL-101, or pharmaceutically acceptable salts thereof.
• the invention also relates to methods for inhibiting migration and/or invasion of breast cancer cells.
• the invention relates to methods for inhibiting migration and/or invasion of breast cancer cells in a subject in need thereof.
• the invention relates to methods for inhibiting migration and/or invasion of breast cancer cells in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor of Formula I or II.
• kits are provided.
• Kits according to the invention include package(s) comprising compounds or compositions of the invention.
• kits comprise a HDAC inhibitor, or a pharmaceutically acceptable salt thereof, and either a Her2 inhibitor or PI3K inhibitor, or a pharmaceutically acceptable salt thereof.
• packaging means any vessel containing compounds or compositions presented herein.
• the package can be a box or wrapping.
• Packaging materials for use in packaging pharmaceutical products are well-known to those of skill in the art. Examples of pharmaceutical packaging materials include, but are not limited to, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
• the kit can also contain items that are not contained within the package, but are attached to the outside of the package, for example, pipettes.
• Kits can further contain instructions for administering compounds or compositions of the invention to a patient. Kits also can comprise instructions for approved uses of compounds herein by regulatory agencies, such as the United States Food and Drug
• Kits can also contain labeling or product inserts for the compounds.
• the package(s) and/or any product insert(s) may themselves be approved by regulatory agencies.
• the kits can include compounds in the solid phase or in a liquid phase (such as buffers provided) in a package.
• the kits can also include buffers for preparing solutions for conducting the methods, and pipettes for transferring liquids from one container to another.
• BF 3 -ether (1300 ml, 2.0 equiv.) was added dropwise over a period of 60 min., while the inner temperature was maintained below 15 °C.
• the reaction mixture was stirred at 15-20 °C for 1-2 hr. and stopped when a low level of benzonitrile remained.
• IN HC1 (2500 ml) was added dropwise while maintaining the inner temperature below 30 °C.
• NaOH (20%, 3000 ml) was added dropwise to bring the pH to about 9.0, while still maintaining a temperature below 30 °C.
• the reaction mixture was adjusted to a pH of about 8.5-9 through addition of HCl (6N), resulting in precipitation.
• the mixture was concentrated under reduced pressure. Water (3000 ml) was added to the residue with intense stirring and the precipitate was collected by filtration. The product was dried in an oven at 45 °C overnight (340 g, 79% yield).
• Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten point three fold dilution series was made.
• the compounds were diluted in assay buffer (50 mM HOPES, pH 7.4, 100 mM Kill, 0.001% Tween-20, 0.05% BASE, 20 ⁇ TEC) to 6 fold their final concentration.
• the HDAC enzymes purchased from BPS Biosciences
• the dipeptide substrate and trypsin at 0.05 ⁇ final concentration were diluted in assay buffer at 6 fold their final concentration.
• the final enzyme concentrations used in these assays were 3.3 ng/ml
• HDAC1 0.2 ng/ml
• HDAC2 0.08 ng/ml
• HDAC 3 2 ng/ml
• the final substrate concentrations used were 16 ⁇ (HDAC1), 10 ⁇ (HDAC2), 17 ⁇ (HDAC3) and 14 ⁇ (HDAC6).
• Five ⁇ of compound and 20 ⁇ of enzyme were added to wells of a black, opaque 384 well plate in duplicate. Enzyme and compound were incubated together at room temperature for 10 min..
• Five ⁇ of substrate was added to each well, the plate was shaken for 60 seconds and placed into a Victor 2 microliter plate reader. The development of fluorescence was monitored for 60 min. and the linear rate of the reaction was calculated.
• the IC 50 was determined using Graph Pad Prism by a four parameter curve fit.
• a panel of 16 breast cancer cell lines were treated with either Compound A, doxorubicin, GDC-0941, or lapatinib and the drug combinations for 48 hours, and cell viability was measured by the MTA assay. Synergy between Compound A and the partner compounds were calculated using CalcuSyn. Cell viabilities were used to calculate "Fraction Affected” (Fa) and "Combination Index” (CI) values using the Chou-Talalay method. Any combination with a CI value ⁇ 0.70 at a Fa value between 0.25 and 0.75 was defined as positive synergy.
• Example 7 PI3K Inhibitor GDC-0941 is Potentiated by HDAC6 Selective Inhibitors
• Compound A and Compound C are HDAC6 selective inhibitors with similar low nM potency with 13 fold and 1,500 fold selectivity of HDAC6 over class I HDACs, respectively. The results of this experiment are shown in Figure 1.
• the Her2 + breast cancer cell lines MDA-MB-453 or BT-474 were incubated with combinations of a HDAC6 inhibitor, Compound A or Compound C, and one of the other anti-breast cancer
• IC 50 Inhibitory Concentration at which 50% of the cells are viable
• HDAC6 inhibition has been investigated on Her2 + breast cancer cell growth and cell migration using an HDAC6 inhibitor alone or in combination with either a Her2 inhibitor (lapatinib) or a PI3K inhibitor (GDC-0941, IPI-145, and CAL-101).
• Anti-tumor activity of Compound A was investigated using a panel of nearly 100 human tumor cell lines derived from the major cancer types, and Her2 + breast cancer cells were among the most sensitive cells to Compound A. Combinations of Compound A with either the Her2 inhibitor lapatinib or PI3K inhibitor GDC-0941 demonstrated synergistic cytotoxicity against these cancer cells. To illustrate that the effects were due to HDAC6 inhibition, the highly selective HDAC6 inhibitor Compound C was used, which has greater than 1,500 fold of selectivity against HDAC6 over Class I HDACs (HDAC1, 2 and 3).
• Compound C was able to sensitize Her2 + breast cancer cells MDA-MB-453 and BT-474 to lapatinib and PI3K inhibitors (IPI-145, GDC-0941 and CAL-101). Compound C also blocked cancer cell migration in the presence or absence of epidermal growth factor (EGF). In agreement with the proposed mechanism of HDAC6 mediated Her2 + breast cancer cell death, Compound A treatment correlated with a decrease of Her2 protein, p-EGFR, and p- AKT in the Her2 + breast cancer cell line MDA-MB-453. By taking advantage of the highly selective HDAC6 inhibitor Compound C, growth and migration suppressive activities by HDAC6 inhibition in Her2 + breast cancer cells were shown.
• the protocol for the Migration Assay was as follows. The compounds were prepared in DMSO at 400 x stock of the final required concentrations.
• A549 cancer cells were compared in the presence or absence of a HDAC6 inhibitor.
• the cancer cells were seeded and grown on a membrane surface, and the cell numbers on the other side of the membrane were counted under a microscope after 12 hours. In addition to migration (Example 10), the cells also had to cross a collagen barrier. A decreased number of migrated cells by the HDAC6 inhibitor suggests an invasion suppression activity of HDAC6 inhibitor.
• the effect of HDAC6 inhibitor on Epidermal Growth Factor (EGF) stimulated cancer cell migration using 20 ng/ml of EGF in the assay was investigated.
• EGF Epidermal Growth Factor
• the protocol for the Invasion Assay was as follows. The compounds were prepared in DMSO at 400 x stock of the final required concentrations.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=52777441

Family Applications (1)

Country Status (5)

Cited By (16)

Families Citing this family (18)

Citations (5)

Family Cites Families (68)

• 2014
  • 2014-10-06 ES ES14851657T patent/ES2929576T3/es active Active
  • 2014-10-06 WO PCT/US2014/059238 patent/WO2015054099A1/en not_active Ceased
  • 2014-10-06 JP JP2016521347A patent/JP6626437B2/ja active Active
  • 2014-10-06 EP EP14851657.8A patent/EP3054952B1/en active Active
  • 2014-10-06 US US14/506,889 patent/US9403779B2/en active Active
• 2016
  • 2016-06-22 US US15/189,554 patent/US10722512B2/en active Active

Patent Citations (5)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events